Want to see CH:KURN full AI Analyst Report?
KURN Stock Chart & Stats
CHF21.42
CHF0.62(3.13%)
At close: 4:00 PM EDT
CHF21.42
CHF0.62(3.13%)
Day’s Range― - ―
52-Week RangeCHF16.46 - CHF34.20
Previous CloseN/A
Volume158.99K
Average Volume (3M)220.18K
Market Cap
CHF698.65M
Enterprise ValueCHF776.03
Total Cash (Recent Filing)CHF7.85M
Total Debt (Recent Filing)CHF11.01M
Price to Earnings (P/E)97.3
Beta1.36
Next Earnings
Mar 17, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.18
Shares Outstanding39,673,230
10 Day Avg. Volume189,484
30 Day Avg. Volume220,179
Financial Highlights & Ratios
PEG Ratio-3.21
Price to Book (P/B)15.78
Price to Sales (P/S)8.71
P/FCF Ratio-439.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF32.50Price Target Upside51.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.4
Revenue Forecast (FY)CHF207.82M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Scaling And High MarginsThe substantial multi-year revenue increase shows that Kuros is scaling commercial adoption rather than relying on a stagnant niche. Very high gross margins provide room to fund selling, clinical and manufacturing investments, while continued volume growth could support further operating leverage.
Strong Commercial ExpansionBroader distributor coverage, rising surgeon utilization and expanding patient experience strengthen Kuros's commercial position in bone healing. These adoption gains can reinforce awareness, support repeat demand and create a durable foundation for growth across spine and orthopedic procedures.
Conservatively Financed Balance SheetVery low leverage gives Kuros greater flexibility to invest in capacity, commercialization and clinical development without a heavy interest burden. The conservative capital structure also improves resilience if the manufacturing ramp or cash-conversion pressures require additional time before fully benefiting from growth.
Bears Say
Weak Cash ConversionThe shift to negative operating and free cash flow despite improved earnings indicates that reported profitability is not yet translating consistently into internally generated funding. If this persists, Kuros may face greater liquidity sensitivity while financing expansion and ongoing commercial investment.
Manufacturing Ramp May Pressure MarginsBuilding U.S. production should support localized fulfillment and future scale, but the transition creates a near-term margin headwind through start-up inefficiencies and transformation spending. This may temporarily offset operating leverage and make earnings progress less predictable over coming quarters.
Clinical Evidence Remains IncompleteAlthough existing clinical evidence is supportive, several important studies have not completed enrollment, so comparative claims and broader payer or institutional adoption remain partly dependent on future results. Delayed completion could extend the time needed to fully validate and expand the franchise.
Kuros Biosciences News
KURN FAQ
What was Kuros Biosciences Ltd.’s price range in the past 12 months?
Kuros Biosciences Ltd. lowest stock price was CHF16.46 and its highest was CHF34.20 in the past 12 months.
What is Kuros Biosciences Ltd.’s market cap?
Kuros Biosciences Ltd.’s market cap is CHF698.65M.
When is Kuros Biosciences Ltd.’s upcoming earnings report date?
Kuros Biosciences Ltd.’s upcoming earnings report date is Mar 17, 2027 which is in 170 days.
How were Kuros Biosciences Ltd.’s earnings last quarter?
Kuros Biosciences Ltd. released its earnings results on Aug 13, 2026. The company reported CHF0.059 earnings per share for the quarter, beating the consensus estimate of CHF0.058 by CHF0.002.
Is Kuros Biosciences Ltd. overvalued?
According to Wall Street analysts Kuros Biosciences Ltd.’s price is currently Undervalued.
Does Kuros Biosciences Ltd. pay dividends?
Kuros Biosciences Ltd. does not currently pay dividends.
What is Kuros Biosciences Ltd.’s EPS estimate?
Kuros Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kuros Biosciences Ltd. have?
Kuros Biosciences Ltd. has 39,673,230 shares outstanding.
What happened to Kuros Biosciences Ltd.’s price movement after its last earnings report?
Kuros Biosciences Ltd. reported an EPS of CHF0.059 in its last earnings report, beating expectations of CHF0.058. Following the earnings report the stock price went up 0.609%.
Which hedge fund is a major shareholder of Kuros Biosciences Ltd.?
Currently, no hedge funds are holding shares in CH:KURN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kuros Biosciences Ltd.
Kuros Biosciences AG functions as a biopharmaceutical enterprise, dedicated to both the development and market introduction of advanced therapeutic solutions for tissue regeneration and bone repair. Its operations span across the United States, the European Union, and other global regions. The company's business activities are structured into three main segments: Medical Devices, Pharmaceuticals, and a Legacy Portfolio. Its orthobiologics product line includes MagnetOs Granules and MagnetOs Putty, available in EU and US markets for various orthopedic, spinal, and dental applications. Within its fibrin/PTH orthobiologics pipeline, KUR-111 has successfully completed a Phase 2b clinical trial for treating tibial plateau fractures. Similarly, KUR-113 has concluded its Phase 2b clinical trial for tibial shaft fractures and is currently undergoing a Phase II trial for spinal interbody fusion procedures. Additionally, Kuros offers sealant products such as Neuroseal, a synthetic tissue sealant marketed in the EU and US, engineered to prevent cerebrospinal fluid leakage after cranial or spinal surgeries. The company also engages in a collaborative endeavor with Checkmate Pharmaceuticals LLC for the advancement of CYT003, intended for oncology treatments. Kuros Biosciences AG is headquartered in Schlieren, Switzerland.
KURN Company Deck
KURN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong set of operational and financial achievements (robust +45% H1 revenue growth, first sustained half‑year profitability with CHF 12.5M adjusted EBITDA and CHF 4.4M net profit, improving gross margins, strong clinical evidence and a clear midterm revenue/margin target). These positives are tempered by planned near‑term investments and transformation costs, expected dilution from the U.S. manufacturing ramp, lumpiness in international revenue, and working capital accumulation that creates short-term liquidity sensitivity. On balance, the transformational investments are framed as deliberate and the company maintained conservative near-term guidance while presenting a credible path to >20% adjusted EBITDA by 2028, so the overall tone is confident with manageable near-term risks.View all CH:KURN earnings summariesKURN Stock 12 Month Forecast
Average Price Target
CHF32.50
▲(51.73% Upside)
Technical Analysis
Molecular Partners AG
―
Lonza Group Ltd
―
Basilea Pharmaceutica
―
Idorsia Ltd
―
Bachem Holding AG
―